# Phase 2 Study of MM-093 to Treat Patients With Uveitis

> **NCT00444743** · PHASE2 · COMPLETED · sponsor: **Merrimack Pharmaceuticals** · enrollment: 20 (estimated)

## Conditions studied

- Uveitis

## Interventions

- **DRUG:** MM-093
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00444743
- **Lead sponsor:** Merrimack Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2008-11
- **Final completion:** —
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2008-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00444743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00444743, "Phase 2 Study of MM-093 to Treat Patients With Uveitis". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00444743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*